Form 4: Corvus Pharmaceuticals CFO Leiv Lea Acquires 300,000 Stock Options

Corvus Pharmaceuticals' Chief Financial Officer, Leiv Lea, reported the acquisition of 300,000 stock options on December 20, 2024.

Summary

• On December 20, 2024, Leiv Lea, the Chief Financial Officer of Corvus Pharmaceuticals, acquired 300,000 stock options.
• The options have an exercise price of $4.99.
• The options vest in equal monthly installments over three years, starting from December 20, 2024, contingent upon continued service with the company.
• The options expire on December 20, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (stock option grant) for a key executive. It doesn't inherently indicate positive or negative performance, but rather incentivizes future performance.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry.
• The vesting schedule of 1/36th monthly over three years is a typical vesting arrangement.
• Comparing the size of the grant to grants made to executives at similar-sized biotech companies (e.g., companies with market caps between $50 million and $200 million) would provide further context.

Key Dates